Browse the evidence

High-protein diets induce insulin resistance and impair glucose homeostasis by promoting gluconeogenesis and reducing peripheral insulin sensitivity, whereas fish protein (specifically cod) improves insulin sensitivity compared to other protein sources.

If you are consuming high amounts of protein, prioritize fish (like cod) over other sources like casein or beef to potentially improve insulin sensitivity. Be aware that very high protein intake, regardless of source, may impair glucose homeostasis in some individuals by increasing gluconeogenesis and insulin resistance.

Pharmacotherapy (e.g., Orlistat) is recommended as an adjunct to lifestyle intervention for patients with BMI >25 (or >23 with comorbidities) who fail to achieve initial goals, but must be discontinued if <5-10% weight loss is achieved after 3 months.

If lifestyle changes alone aren't enough, ask your doctor about Orlistat. It blocks fat absorption. However, it only works if you stick to your diet. If you don't lose at least 5-10% of your weight in 3 months, stop the drug—it's not working for you.

Long-term physical activity (specifically aerobic exercise) promotes neuroplasticity and cognitive health in aging adults by upregulating Brain-Derived Neurotrophic Factor (BDNF), increasing hippocampal volume, and reducing neuroinflammation.

Engage in regular moderate aerobic exercise (e.g., brisk walking, cycling) at least 3 times per week for 12 months or more. This specific protocol has been shown to increase hippocampal volume and reverse 1-2 years of age-related brain loss, directly supporting memory and executive function.

Insulin resistance is a stronger predictor of sleep disordered breathing in women with Polycystic Ovary Syndrome (PCOS) than obesity, age, or testosterone levels.

If you have PCOS, get screened for sleep apnoea even if you are not obese. Your risk is driven largely by insulin resistance, not just your weight. Managing blood sugar and insulin sensitivity is crucial for your sleep health.

Metformin administration (850-1700 mg) reduces caloric intake and hunger ratings in a dose-dependent manner in obese women with type II non-insulin-dependent diabetes.

If you have type 2 diabetes and obesity, metformin can help you lose weight by reducing your appetite and calorie intake, especially if you have struggled to lose weight with diet alone. The study used doses of 850-1700 mg daily, combined with a modest caloric restriction (1200 kcal/day).

Metformin improves glycemic control (reduces HbA1c and fasting blood glucose) in obese women with type II NIDDM, independent of weight loss mechanisms.

Metformin effectively lowers blood sugar levels (HbA1c and fasting glucose) in obese diabetic patients, even when combined with a modest caloric restriction diet.

The number of metabolic syndrome traits (0-5) is positively associated with the incidence of major cardiovascular events, with each additional trait increasing the risk by 22%.

Your cardiovascular risk increases by 22% for every metabolic syndrome trait you have (e.g., high blood pressure, high triglycerides, low HDL, high waist circumference, high blood sugar). Reducing the number of these traits directly lowers your risk of heart attack and stroke.

Chronic oral consumption of thermally processed foods containing advanced glycation endproducts (AGEs) promotes insulin resistance and type 2 diabetes by depleting the antioxidant defenses AGE receptor-1 (AGER1) and sirtuin 1 (SIRT1).

To support your metabolic health, reduce your intake of advanced glycation endproducts (AGEs) by modifying how you cook. Prioritize moist cooking methods like stewing, boiling, or poaching over dry, high-heat methods like grilling, frying, or broiling. Avoid browning or charring foods, as this process significantly increases AGE formation. This simple shift can help preserve your body's natural antioxidant defenses (AGER1 and SIRT1) and improve insulin sensitivity.

Obesity acts as a chronic systemic low-grade inflammation where adipose tissue and its hormones play a central role, linking obesity to insulin resistance and NAFLD.

Managing body fat is not just about weight; it is about reducing the inflammatory signal sent by fat tissue to the liver and pancreas, which is a primary driver of fatty liver disease.

Colonic SCFA mixtures increase plasma Peptide YY (PYY) concentrations, a satiety-stimulating hormone, in both fasting and postprandial states.

Eating fiber-rich foods stimulates the release of Peptide YY (PYY), a hormone that signals fullness to your brain. To manage appetite, ensure your diet includes sufficient fermentable fibers (found in vegetables, fruits, and whole grains) to support natural PYY production.

Short-chain fatty acids (SCFAs), particularly butyrate, produced by gut microbiota fermentation of prebiotics/probiotics, improve insulin sensitivity by activating G-protein-coupled receptors on L-cells to stimulate GLP-1 and PYY release.

Eating prebiotic fibers (like those in chicory, onions, garlic) feeds gut bacteria that produce SCFAs like butyrate. These SCFAs signal your gut to release hormones (GLP-1, PYY) that help regulate blood sugar and appetite.

Peripheral administration of PYY3-36 reduces food intake and 24-hour caloric intake in both normal-weight and obese humans.

Your body naturally releases PYY after eating to signal fullness. In obesity, this signal is often weaker. Research shows that replacing or boosting this hormone can effectively reduce appetite and calorie intake, even in obese individuals, suggesting that targeting this pathway is a viable strategy for weight management.

Low circulating levels of PYY are associated with obesity and reduced satiety in humans.

If you struggle with satiety, your PYY levels might be lower than average. This isn't a character flaw; it's a hormonal signal. Strategies that stimulate PYY release, such as protein-rich meals or specific surgical interventions, may help restore this natural fullness signal.

In older men (aged 65+), total testosterone deficiency (<200 ng/dl) and total estradiol deficiency (<10 pg/ml) are significantly associated with a higher prevalence of hip osteoporosis and an increased risk of rapid hip bone loss.

For men over 65, having low testosterone or estradiol is a strong warning sign for weak bones. If you have these deficiencies, you should get a bone density scan (DEXA) even if you feel healthy, as you are at much higher risk for osteoporosis and rapid bone loss than men with normal levels.

Transdermal testosterone gel (50-100 mg/day) normalizes serum testosterone and free testosterone levels in hypogonadal men with significantly lower discontinuation rates due to skin irritation compared to transdermal patches.

For hypogonadal men, transdermal testosterone gel is an effective treatment that normalizes testosterone levels with a much lower risk of skin irritation and discontinuation compared to patches. Dosing can be adjusted (titrated) to ensure levels stay within the normal range, offering flexibility and better adherence.

Physical activity stimulates the production and release of adiponectin, which enhances glucose uptake and fatty acid oxidation through AMPK activation.

Engage in regular physical activity to naturally boost your adiponectin levels. This hormone helps your muscles take up glucose and burn fat more efficiently. You do not need extreme workouts; consistent activity can reverse the low adiponectin levels associated with sedentary living.

Substituting saturated fatty acids with monounsaturated fatty acids in the diet improves insulin sensitivity, whereas substituting saturated fats with polyunsaturated n-6 fatty acids does not.

To improve insulin sensitivity, focus on replacing saturated fats (like butter) with monounsaturated fats (like olive oil or rapeseed oil). Simply adding more polyunsaturated fats (like corn or sunflower oil) or omega-3 supplements does not appear to improve insulin sensitivity on its own, according to this research.

High activity of the delta-5 desaturase and high levels of long-chain polyunsaturated fatty acids in skeletal muscle are strongly associated with good insulin sensitivity.

While you cannot directly 'dose' desaturase activity, maintaining a muscle fatty acid profile that supports delta-5 desaturase function (via adequate unsaturated fat intake and physical activity) is linked to better insulin sensitivity.

Peripheral administration of Peptide YY (PYY) (3-36) reduces food intake and body weight gain in rodents and reduces appetite in humans, primarily by acting on Y2 receptors in the arcuate nucleus and via vagal afferent signaling.

Peripheral PYY administration reduces food intake in both lean and obese humans. This suggests that therapies mimicking PYY (like GLP-1 agonists which often co-secreted with PYY) can help manage appetite by leveraging the body's natural satiety hormones.

Peripheral administration of Glucagon-like peptide-1 (GLP-1) reduces food intake in a dose-dependent manner in both normal weight and obese subjects, although obese subjects have a blunted postprandial GLP-1 response.

GLP-1 reduces food intake in both lean and obese people. However, obese people have a blunted natural response. Pharmacological GLP-1 agonists (like exenatide and liraglutide) are designed to overcome this by being resistant to degradation and providing a stronger signal.

Forced expression of BMP4 in white adipose tissue induces brown fat-like changes (beige/brite phenotype) in white adipocytes, leading to increased energy expenditure, reduced adiposity, and improved insulin sensitivity.

This research identifies BMP4 as a key protein that, when present in white fat, can transform it into a fat type that burns energy (beige/brite fat). This transformation reduces fat mass and improves how the body handles sugar and insulin. While this is currently a genetic finding in mice, it suggests that therapies targeting BMP4 or its pathways (like p38/MAPK) could potentially help treat obesity and diabetes by leveraging the body's own fat tissue for energy expenditure.

Sustained sleep curtailment (less than 6 hours per night) causally increases the risk of developing type 2 diabetes, hypertension, obesity, and cardiovascular disease through hormonal dysregulation, insulin resistance, and vascular changes.

Prioritize getting 7-8 hours of sleep every night as a non-negotiable health intervention. Chronic sleep restriction (less than 6 hours) is as dangerous for your heart and metabolism as obesity or smoking. You cannot simply 'catch up' on weekends to reverse the long-term metabolic damage. Treat sleep duration with the same seriousness as diet and exercise.

High resistant starch intake improves postprandial insulin and glucose regulation but may increase plasma TMAO levels, a biomarker for cardiovascular disease risk.

If you are insulin resistant, high resistant starch can help blunt blood sugar and insulin spikes after meals. However, be aware that it may also increase TMAO, a marker linked to heart disease risk in some studies. For most people, the metabolic benefits of better blood sugar control outweigh this risk, but those with existing cardiovascular issues should monitor this closely or consult a doctor.

Weight loss in obese non-insulin-dependent diabetes mellitus (NIDDM) patients significantly improves glucose homeostasis by reducing basal hepatic glucose output and ameliorating peripheral insulin resistance through enhanced postreceptor glucose transport activity, without requiring increased absolute insulin secretion.

For obese individuals with type 2 diabetes, losing weight is a powerful tool to improve blood sugar control. This improvement comes from two main changes: your liver produces less sugar when you aren't eating, and your muscles become much better at using the insulin you already have. You do not necessarily need to produce more insulin to achieve better blood sugar levels; instead, your body becomes more sensitive to it. This suggests that focusing on sustainable weight loss can significantly reduce the burden of diabetes management.